טוען...
Zofenopril Protects Against Myocardial Ischemia–Reperfusion Injury by Increasing Nitric Oxide and Hydrogen Sulfide Bioavailability
BACKGROUND: Zofenopril, a sulfhydrylated angiotensin‐converting enzyme inhibitor (ACEI), reduces mortality and morbidity in infarcted patients to a greater extent than do other ACEIs. Zofenopril is a unique ACEI that has been shown to increase hydrogen sulfide (H(2)S) bioavailability and nitric oxid...
שמור ב:
הוצא לאור ב: | J Am Heart Assoc |
---|---|
Main Authors: | , , , , , , , , , , , , , |
פורמט: | Artigo |
שפה: | Inglês |
יצא לאור: |
John Wiley and Sons Inc.
2016
|
נושאים: | |
גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5015391/ https://ncbi.nlm.nih.gov/pubmed/27381758 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.116.003531 |
תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|